Targeting a new immune checkpoint to improve cancer therapy
Official title: Advancing cancer therapy: Developing antibody blockade targeting a novel immune checkpoint, LAIR1/CD305
Funded at Immunogenik, INC. · NIH-11063877 · Data updated 2026-11-12
This study is looking at a new way to help people with advanced cancer by blocking a specific part of the immune system called LAIR1, which could make it easier for the body to fight tumors.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Immunogenik, INC. NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project start | June 9, 2025 |
| Project end | May 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $398,997 |
| NIH project number | 1R41CA298020-01 |
| Project ID | NIH-11063877 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with advanced cancer who may benefit from enhanced immune responses against their tumors.
✕Less likely to help
Patients with early-stage cancer or those whose tumors do not express the LAIR1 checkpoint may not benefit from this research.
What this research studies
This research investigates how to enhance cancer treatment by blocking a specific immune checkpoint called LAIR1, which is found on certain immune cells in tumors. By inhibiting LAIR1, the study aims to improve the immune response against tumors, making it easier for the body to fight cancer. The approach involves using antibodies to block LAIR1 and studying its effects on immune cell behavior and tumor interactions in the lab. The ultimate goal is to develop a new therapy that can be used in clinical settings to help patients with advanced cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that improve patient outcomes and responses to therapy.
How similar studies have gone: Previous research has shown promising results in targeting immune checkpoints for cancer therapy, suggesting that this approach could be effective.
Where this research is happening
-
Immunogenik, INC.
Gainesville, United States Active
Researchers
- Principal investigator: Huang, Jianping — Immunogenik, INC.
- Study coordinator: Huang, Jianping
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.